Although the importance of the liver in clinical pharmacology is widely recognized, little is known in humans concerning its function in vivo at the hepatocyte level and how pharmacological functions are altered in the setting of advanced liver disease. Several recent proof-of-principle studies with first-generation DAAs have demonstrated the feasibility of serial liver sampling for pharmacological studies. These studies have begun to describe the liver-to-plasma concentration ratio and how this ratio is altered in the setting of advanced liver disease. These data are particularly relevant to individuals with substance-use disorders because many have advanced liver disease as a consequence of long-standing viral hepatitis infection or continued use of hepatotoxins such as alcohol. Future research should attempt to develop standardized and reproducible methods to assess liver drug concentration, complex drug interactions, and pharmacogenomics in humans to permit elucidation of the clinical pharmacology within the liver.
The liver is tremendously important from a pharmacokinetic perspective by playing a predominant role in drug metabolism and elimination. Hepatic clearance of a drug is influenced by the inherent ability of hepatocytes to remove the drug (ie, intrinsic clearance), the flow of blood to the liver, and the relationship of drug binding to plasma proteins. 1, 2 A firm foundation of how liver dysfunction (eg, cirrhosis) changes each of these parameters and the resulting effect on plasma pharmacokinetics was established by Wilkinson et al. 1, 3 However, a paucity of data exists on the effect of liver dysfunction on human intrahepatic pharmacokinetics. The evaluation of intrahepatic pharmacokinetics, as well as pharmacokinetics at the cellular (ie, hepatocyte) level, could be important for maximizing the efficacy and minimizing the toxicity of drugs that undergo significant hepatic clearance. Thus, significant gaps exist concerning the understanding of liver function and intrahepatic pharmacology.
To begin to address these gaps, several studies of human liver pharmacology have been conducted in patients with hepatitis C virus (HCV) infection. [4] [5] [6] HCV replicates principally in hepatocytes, where it establishes a cycle of inflammation and fibrosis that can ultimately culminate in end-stage liver disease, cirrhosis, and hepatocellular carcinoma. 7 HCV is very transmissible in blood, resulting in high prevalence among injection drug users, many of whom have advanced liver disease based on long duration of infection. Although interferon was previously the cornerstone of HCV therapeutics, current regimens consist entirely of direct-acting antivirals (DAAs) that target the intracellular viral life cycle, resulting in improved efficacy. 8 DAA concentration within an infected cell is likely an important determinant of Intrahepatic mRNA for microarray analysis of genes associated with liver fibrosis CNB, core needle biopsy; CXCL10, C-X-C motif chemokine 10; FNA, fine-needle aspiration; HCV, hepatitis C virus; IP-10, interferon-gamma inducible protein-10; PEG-IFN, pegylated-interferon; ribavirin, RBV; TVR, telaprevir; VNV, vaniprevir.
efficacy, treatment failure, development of viral resistance, and drug toxicity, as has been observed concerning the intracellular concentration of other antivirals.
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Intrahepatic drug concentrations, however, have very rarely been measured. Because unbound systemic drug concentrations are assumed to equate with those in the liver, plasma drug concentrations are considered surrogates for liver concentrations. 9, 12 This relationship, however, likely varies by DAA and patient population, as genetics and disease states can modulate intracellular transporters and metabolizing enzymes, thereby affecting intracellular drug concentration. 13 For example, functional single-nucleotide polymorphisms of the organic anion transporter polypeptide (OATP)1B1 are associated with a decrease in the transport function of HIV-1 protease inhibitors and ritonavir. 14, 15 To gain an understanding of liver-plasma drug concentration relationships and factors that influence these relationships, direct hepatocyte drug concentration measurements are needed. An enhanced understanding of these relationships could improve dose selection and could guide dose modifications, particularly in the setting of liver dysfunction. As discussed below, several completed studies have begun to discern these relationships.
Feasibility of Assessing Intrahepatic Drug Concentration
Studies using human liver tissue collected by either fine-needle aspiration (FNA) or core needle [20] [21] [22] Basolateral influx transporters (sinusoidal blood → intrahepatic)
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biopsy (CNB) have measured first-generation DAA concentrations (Table 1 ). In a study of liver pharmacokinetics and pharmacodynamics, 15 genotype 1a/b chronic HCV-infected patients received telaprevir, pegylated-interferon-alpha-2a, and ribavirin with serial FNAs. 4 Interestingly, liver telaprevir concentrations were significantly lower compared with plasma, with median liver-to-plasma ratios ranging from 0.47 to 0.72. In rats and mice, liver telaprevir concentrations were 35 times higher or 5.7-16 times higher, respectively, relative to plasma. 16, 17 Transporters often mediate unbound drug and metabolite influx into hepatocytes or efflux into sinusoidal blood or bile (Table 2) . 13 Because tissue distribution and relative abundance of transporter proteins differ substantially between species, the relevance of some preclinical models to humans may be questioned. 18 For example, the mRNA expression of MDR1 (human)/Mdr1 (animal) genes, encoding for the efflux transporter P-glycoprotein (P-gp), varies substantially not only between species, but between different organs in the same species. P-gp mRNA expression is increased in human liver and kidney compared with rats, whereas in the gastrointestinal tract the inverse occurs -expression is lower in humans than rats. 19 Similarly, although present in humans, OATP1B1 is absent altogether in rodents and dogs. 18 Telaprevir is an inhibitor and substrate of P-gp and an inhibitor of OATP1B1 and OATP2B1 (Table 2) . [20] [21] [22] Thus, speciesrelated differences in the expression and distribution of P-gp and OATPs may partially explain the discrepant results comparing telaprevir studies in humans with those performed preclinically. Consequently, an incomplete understanding of protein abundance in similar organs between species or in organs of the same species complicates translation of findings from preclinical models to humans. To address these data gaps, proteomic screens for determination of drug transporter expression and localization should be pursued. As preclinical models are used extensively in the evaluation of investigational agents, it is important to consider interand intraspecies differences as they relate to metabolism and transporter profiles of the drug under investigation.
In another DAA study of intrahepatic and plasma drug concentrations, vaniprevir concentrations were assessed in 3 adult chronically HCV-infected men (Table 1) . 5 Different than telaprevir, vaniprevir liverto-plasma concentration ratios ranged from ß70 to 280, indicating substantially higher liver concentrations compared with plasma. Interestingly, 1 patient with advanced fibrosis had the highest liver-to-plasma ratio. Although limited to 1 patient, the effect of advanced fibrosis on liver drug concentrations has not been noted previously and might influence intrahepatic pharmacokinetics of medications with substantial liver metabolism. For example, decreased hepatic blood flow as a result of portal hypertension, reduced cytochrome P450 isoenzyme activity, and changes in the expression of efflux transporters, have been associated with chronic HCV infection and advanced fibrosis. 2, 13, 23 These factors, for example, could account for increased plasma grazoprevir concentrations observed in patients with cirrhosis.
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Measurement of Intrahepatic Viral Kinetics
To date, the clearance rate of HCV-infected hepatocytes with combination DAA regimens has not been assessed. 26 In the first study to evaluate DAA treatment-induced intrahepatic HCV RNA decline, hepatic HCV RNA declined more slowly compared with plasma between baseline and day 4, whereas decline rates were equivalent from days 4 to 15, and virus was undetectable by week 8 in all samples. 4 Viral kinetic modeling suggested that liver HCV RNA decay is markedly delayed compared with plasma in telaprevirtreated patients.
Telaprevir resistant mutations were also assessed. 4 Pretreatment, only wild-type virus was detected in plasma and liver. Posttreatment initiation, telaprevirresistant variants in plasma were observed in 7 patients, whereas only wild-type virus was detected in liver at any time. Although differences in resistant isolates may exist between body compartments, 2 important study limitations require consideration: (1) only 8 of 15 patients underwent a week 8 FNA procedure, and (2) there was potential liver sampling bias. Consequently, the FNA procedure may not have sampled liver regions in which telaprevir-resistant variants were located.
Measurement of Intrahepatic Gene Expression
Liver gene expression in FNA or CNB samples has been evaluated in several studies. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Many older studies documented an association between viral nonresponse and increased expression of hepatic and peripheral interferon-associated genes, especially interferon-gamma inducible protein-10 (IP-10; also known as CXCL10 [C-X-C motif chemokine 10]), in HCV-infected patients on interferon and ribavirin. [27] [28] [29] [30] The addition of telaprevir to pegylatedinterferon/ribavirin changed this relationship; baseline peripheral and intrahepatic IP-10 levels (collected by FNA) were not predictive of viral response. 31 Liver gene expression in samples collected by FNA has also identified liver-enriched genes in both humans and dogs. 37 The FNA procedure has also been used to assess changes in fibrosis-related gene expression in a trial of the investigational antifibrotic agent simtuzumab. 32 These studies illustrate the feasibility of gene expression analysis in samples collected by FNA, procedures that could be employed to evaluate changes in intrahepatic gene and protein expression induced by illicit drug use or agents used in substance-use disorder treatment.
Current Limitations and Future Directions for Liver Sampling
Although serial liver sampling is feasible, limitations include potential blood contamination and measurement bias because of small sample quantities. Liver sampling via an ultrasound guided probe appears to reduce the degree of blood contamination. In addition, quantitation of liver-enriched gene mRNA expression in FNA samples could be used to standardize the amount of liver tissue contained within serially collected samples. 37 Several of the same genes were also enriched in dog liver, illustrating the potential feasibility of the procedure across animal species.
An additional oft-cited concern is the invasiveness of the liver sampling procedure as a potential deterrent to subject participation in trials using the procedure. In reality, this has not been the case, in which no study participant has discontinued participation because of the liver sampling procedure. Rather, the vast majority of subjects opted to undergo additional optional procedures, as procedure-related adverse events have been minimal (Table 1) .
However, several experimental design issues merit further investigation. First, the number of analyses that can be performed on a single sample is limited by the small sample quantity. As progressively smaller quantities of sample are required for laboratory assays, it is likely that this situation will continue to improve going forward. Second, the generalizability of results to the entire liver of those obtained from sampling one region requires further assessment. Hepatocyte drug disposition may vary according to portal and venous blood flow rates as well as regional differences in metabolism and biliary excretion. [1] [2] [3] 9 Studies should therefore readdress the relationship between intrahepatic drug concentrations, hepatic blood flow, and the abundance and regional expression of hepatic transporters and metabolizing enzymes using modern, sophisticated techniques (Table 3 ). For instance, fibrogenesis ultimately culminating in cirrhosis and end-stage liver disease results in collagen replacement of the normal hepatic parenchyma. Given the dynamic nature of liver remodeling during fibrogenic processes, hepatic drug concentration measurements at the hepatocyte level might be more precise and informative than classic bulk tissue approaches.
Conclusions
Although the liver is fundamental to clinical pharmacology, significant gaps exist in our understanding of liver physiology as it relates to human drug metabolism and biliary excretion. Development of standardized and reproducible methods to assess liver drug concentration in humans is a research priority to enhance our understanding of the relationship between plasma and liver drug concentrations. Medication doses selected based on intrahepatic drug concentrations could lead to more accurate dose determinations, especially in cases of medications that have small therapeutic-to-toxicity ratios and where the liver is the site of intended pharmacologic effect. Such data could also guide dose adjustment recommendations in the setting of profound liver dysfunction, such as in individuals with decompensated cirrhosis. The alterations in liver pharmacology that occur in the setting of advanced liver disease are also significantly underappreciated. These data are of tremendous relevance to those with a history of substance-use disorders, many of whom are coinfected with HIV and viral hepatitis. The demonstration of the feasibility of serial liver sampling for measurement of liver drug concentrations indicates that tools currently exist to significantly improve our understanding of the liver's role in clinical pharmacology.
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